Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Sickle cell disease: an update

Emma Conway O'Brien, Sahla Ali and Timothy Chevassut
Download PDF
DOI: https://doi.org/10.7861/clinmed.2022-0143
Clin Med May 2022
Emma Conway O'Brien
AUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK
Roles: haematology registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emma.conwayo'brien@nhs.net
Sahla Ali
AUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK
Roles: haematology registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Chevassut
BUniversity Hospitals Sussex NHS Foundation Trust, Brighton, UK and Brighton and Sussex Medical School, Falmer, UK
Roles: professor of haematology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Sickle cell disease is a common inherited disorder that is characterised by chronic haemolysis and vaso-occlusive episodes, resulting in severe pain and end-organ damage. The most frequent acute manifestation of sickle cell disease is a painful vaso-occlusive crisis, which can, in some cases, develop into a sickle chest crisis: a life-threatening complication of sickle cell disease that requires early recognition and prompt intervention to prevent progressive respiratory failure. In addition to the acute complications, patients with sickle cell disease are also at risk of a number of chronic complications that require multidisciplinary specialist input.

KEYWORDS:
  • sickle cell disease
  • haemoglobinopathy
  • sickle chest crisis
  • veno-occlusive crisis

Key points

  • Patients with sickle cell disease are usually hyposplenic and should be considered to be immunocompromised.

  • Chest crisis is a life-threatening acute complication of sickle cell disease and may follow the onset of a painful crisis.

  • Clinical markers of severity in chest crisis include rising respiratory rate, worsening hypoxia, thrombocytopenia, progressive anaemia, multi-lobar involvement on chest X-ray and neurological impairment.

  • Patients should have access to care at specialist haemoglobinopathy centres. Expert input is required to prevent end-organ damage and optimise life expectancy.

  • Individual and structural discrimination against patients with sickle cell disease is regrettably common in the UK and is associated with worse patient outcomes.

Introduction

Sickle cell disease (SCD) originates in areas with high prevalence of falciparum malaria due to the selective advantage conferred by the heterozygous state. African and African-Caribbean populations have the highest incidence, with sickle phenotypes also observed in Mediterranean, Indian and Middle Eastern communities.1,2 Haemoglobin (Hb) S results from a valine to glutamic acid substitution at position 6 of the beta globin chain. SCD arises in individuals who are homozygous for HbS, or in those with a compound mutation, such as HbSC disease (Fig 1; Box 1)1,2. Sickle cell carriers (HbAS) are typically asymptomatic but may experience vaso-occlusive crises when extremely hypoxic.1

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Photomicrography showing red cell changes. a) Haemoglobin SS disease with numerous sickle cells. b) Haemoglobin SC disease with target and sickle cells.

View this table:
  • View inline
  • View popup
Box 1.

Genotypes associated with sickle cell disease

When deoxygenated, HbS forms insoluble, rod-like structures that aggregate and deform the red cell membrane. This results in chronic haemolytic anaemia and episodes of vaso-occlusion due to aggregation of sickled red cells, leading to pain, tissue hypoxia and end-organ damage.2 The mechanisms surrounding vaso-occlusion are complex, involving mechanical obstruction due to rigid sickled erythrocytes, cellular adherence to vascular endothelium, nitric oxide-induced vasospasm and inflammatory acute phase reactions.1,2

SCD is variable in its phenotype, partly due to concurrent mutations (notably genotypes resulting in raised fetal haemoglobin (HbF)).3 SCD manifests with various acute presentations and also has long-term consequences (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Complications of sickle cell disease

Management of a painful crisis

Case 1

A 23-year-old man with SCD presented with a 3-day history of pain in both legs, his lower back and his right shoulder. He reported that he had not been able to control his pain at home with paracetamol, ibuprofen and oral oxycodone. He had a new productive cough.

Acute veno-occlusive crisis (VOC) is a common emergency presentation. Precipitants include dehydration, hypoxia, hypothermia or infection.2 Management hinges on adequate pain control with paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS; if tolerated) and opioids.2 Patients may have a personalised management plan. Patients should be kept warm, well hydrated and given oxygen if saturations are outside the patient's target range.2

Individuals with HbSS are usually hyposplenic due to auto-infarction of the spleen in childhood.2 Careful assessment and low threshold for antimicrobial therapy is required. Penicillin V prophylaxis should be held and restarted on antimicrobial completion. Thromboprophylaxis is important: SCD increases the risk of venous thromboembolism. The local haematology team should be contacted and any planned blood transfusions discussed.

Many patients face difficulties accessing timely pain relief when seeking emergency care for painful crises, and perceived discrimination in this setting is associated with a negative impact on care.4 The No One's Listening report, an All-Party Parliamentary Group inquiry published in November 2021, found serious failings in the treatment received by patients with SCD in the UK. Misconceptions of patients as ‘difficult’ or ‘opiate seekers’ were common, and some patients reported incidents of overt racism.5

Sickle chest crisis

Case 1 continued

The patient was started on paracetamol, naproxen, oxycodone modified-release and pro re nata OxyNorm. He was given intravenous fluids and antibiotics for lower respiratory tract infection as per local trust guidelines. After 2 days, he reported some new chest pain and shortness of breath. His oxygen saturations were 89% on air. A chest X-ray showed new left basal consolidation.

Acute chest crisis is a life-threatening complication of SCD. The definition of a sickle chest crisis is an acute illness characterised by fever and/or respiratory symptoms associated with pulmonary infiltrate on a chest X-ray.6 Thus, a sickle chest crisis encompasses a broad range of underlying pathologies. Chest crisis can arise spontaneously or, in half of cases, follow a VOC. Low oxygen tension increases red cell sickling and vaso-occlusion of pulmonary capillaries, worsening hypoxia and promoting further sickling. Opiate narcosis causing respiratory depression can contribute, as can uncontrolled rib pain leading to hypoventilation. Opiate requirements and toxicity, respiratory rate, and fluid balance should, therefore, be frequently reassessed in all patients.7 Incentive spirometry can prevent hypoventilation and atelectasis.8

Hypoxic adults need an arterial blood gas to establish partial pressure of oxygen (PaO2). A PaO2 <8 kPA or patients in respiratory distress with peripheral saturations <85% on air should trigger intensive care review.8 Untreated, chest crisis can result in progressive respiratory compromise and can be fatal. Predictors of multiorgan failure in chest crisis include thrombocytopenia, falling Hb, increasing respiratory rate, worsening hypoxia, multi-lobar involvement on chest X-ray and neurological compromise.8 As infection can trigger a chest crisis, then blood and sputum cultures, and nasopharyngeal aspirate for respiratory viruses should be taken.7

All patients need an early crossmatch: top up / exchange transfusions can be lifesaving.8 Other aspects of treatment include antibiotics, careful fluid balance, oxygen and early consideration of escalation to intensive care.9

Longer-term management considerations

Input from a haemoglobinopathy specialist improves outcomes. A multidisciplinary approach aids diagnosis and management of end-organ damage. Patients with SCD require a holistic approach that recognises the impact of chronic pain and ill-health on education and employment, and may benefit from input from allied health professionals (such as psychologists, occupational and physiotherapists, and social workers).

Long-term management of SCD is focused on prevention of infection and end-organ damage. Lifelong penicillin V and vaccination against meningococcus, pneumococcus and Haemophilus influenzae B aim to prevent infection with encapsulated organisms. SARS-CoV-2 and annual influenza vaccination should be encouraged, and folic acid replacement is required. Hydroxycarbamide reduces rates of VOC, chest crisis and need for transfusion, and is effective and well tolerated from infancy.10,11 Hydroxycarbamide may lower mortality.12 Current guidance is to offer hydroxycarbamide from 9 months of age regardless of disease severity.12 The mechanism of action is multifactorial and includes increased production of HbF.3

Regular top-up or exchange transfusions may be beneficial for some individuals.1 Women of childbearing age should be counselled on contraception and ideally reviewed by an obstetric specialist prior to conceiving. Medications may need to be reviewed for teratogenicity and shared haematology/obstetrics antenatal care is required.1

New developments

Several new agents are on the horizon. Crizanlizumab, a P-selectin targeted monoclonal antibody (mAb), has recently been approved for the prevention of VOC in individuals aged over 16 years with SCD. Voxelotor is an oral HbS polymerisation inhibitor that reduces haemolysis. L-glutamine reduces hospital admissions, chest crisis and veno-occlusive events.1,2 Neither are currently approved by the National Institute for Health and Care Excellence.

Haematopoietic stem cell transplant can be curative in the <20% of individuals with a matched donor, but it has risks. Finally, there is considerable interest in the potential for gene therapy, with various approaches including restoration of normal HbA function, increasing HbF expression or inducing expression of modified ‘anti-sickling’ haemoglobin.2,13

  • © Royal College of Physicians 2022. All rights reserved.

References

  1. ↵
    1. Ware RE
    , de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017;390:311–23.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Darbari DS
    , Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol 2020; 105:237–46.
    OpenUrl
  3. ↵
    1. Platt OS
    , Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652–6.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Haywood C Jr.
    , Lanzkron S, Bediako S, et al. Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease. J Gen Intern Med 2014;29:1657–62.
    OpenUrlCrossRefPubMed
  5. ↵
    1. All-Party Parliamentary Group on Sickle Cell and Thalassaemia, Sickle Cell Society
    . No one's listening: an inquiry into the avoidable deaths and failures of care for sickle cell patients in secondary care. Sickle Cell Society, 2021.
  6. ↵
    1. Ballas SK
    , Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010;85:6–13.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Vichinsky EP
    , Styles LA, Colangleo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997;89:1787–92.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Howard J
    , Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol 2015;169:492–505.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Vichinsky EP
    , Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000;342:1855–65.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Charache S
    , Scott JC, Charache P. Acute chest syndrome in adults with sickle cell anaemia. Arch Intern Med 1979;139:67.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wang WC
    , Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663–72.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Qureshi A
    , Kaya B, Pancham S, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. A British Society for Haematology Guideline. Br J Haematol 2018;181:460–75.
    OpenUrlPubMed
  13. ↵
    1. Telen M
    . Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events? Blood Adv 2020;4:3457–65.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Sickle cell disease: an update
Emma Conway O'Brien, Sahla Ali, Timothy Chevassut
Clinical Medicine May 2022, 22 (3) 218-220; DOI: 10.7861/clinmed.2022-0143

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sickle cell disease: an update
Emma Conway O'Brien, Sahla Ali, Timothy Chevassut
Clinical Medicine May 2022, 22 (3) 218-220; DOI: 10.7861/clinmed.2022-0143
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Key points
    • Introduction
    • Management of a painful crisis
    • Sickle chest crisis
    • Longer-term management considerations
    • New developments
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Lymphocytosis and chronic lymphocytic leukaemia: investigation and management
  • Multiple myeloma: what a non-haematologist should know
  • Acute leukaemia: no reason to panic
Show more CME: Haematology

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2023 by the Royal College of Physicians